IDP Pharma announces first patient dosed in a Phase 1/2 Clin

IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader

IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Spain , Salamanca , Castillay Leóp , Valdecilla , Cantabria , Amsterdam , Noord Holland , Netherlands , Barcelona , Comunidad Autonoma De Cataluna , Hebron , Israel General , Israel , Laura Nevola , Arrixaca Murcia , Universitario Marqu , Enrique Ocio , Valentin Caba , Division Of Oncology , Stanford University , Lifespring Life Sciences Communication , Virgen De La Arrixaca , Professor Dean Felsher , Scientific Adviser , Santiago Esteban , Chief Executive Officer , Professor Enrique Ocio , Hospital Universitario Marqu , Hospital Vall , Hospital Universitario , Parc Cient , Chief Executive , Spring Life Sciences Communication ,